Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Bioalliance Pharma Announces Its Participation in the Natixis Securities Midcap Healthcare Conference

Abstract:
BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics which address resistance issues in cancer, HIV and opportunistic infections, today announced that it will take part in an international business conference devoted to meetings between institutional investors and healthcare/biotech companies:

* The Natixis Securities MidCap Healthcare Conference, November 16, Paris.

(at Salons France Amériques, 9-11 Avenue Franklin Roosevelt)

Dominique Costantini, BioAlliance Pharma's President and CEO, will present the company to institutional investors in plenary session #1 at 9.45am on Friday, November 16.

Bioalliance Pharma Announces Its Participation in the Natixis Securities Midcap Healthcare Conference

PARIS, France | Posted on November 12th, 2007

BioAlliance is the first French high-growth company to have developed a product on the basis of innovative academic research results and to have completed the drug development process all the way up to and including market launch. With a broad and diversified portfolio of innovative products (including three in Phase III trials and a number of promising preclinical programs in cancer and HIV), the company has highlighted its determination to achieve growth throughout Europe.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance. The company is currently developing three innovative clinical-phase products based on the Lauriad® muco-adhesive technology (which enables early, prolonged release of therapeutic agents at the site of the disease; one product is already on the market in France and two phase III clinical trials are ongoing - Loramyc® and acyclovir Lauriad®) and the Transdrug® nanoparticle technology (designed specifically for intracellular targeting of resistant cells: a pivotal phase III primary liver cancer trial is underway with doxorubicin Transdrug®). The company is also developing a new therapeutic entities program focused on the oncology and HIV market.

In 2007, the company established two strategic partnerships to sell its first product (Loramyc®) in the USA and Europe (where the French market launch was announced in September 2007).

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website ( http://www.amf-france.org ) or on BioAlliance Pharma S.A.'s website ( http://www.bioalliancepharma.com ).

For press releases and other company information, visit http://www.bioalliancepharma.com .

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
President and CEO
Tel.: +33 1 45 58 76 01

or
Nicolas Fellmann
CFO
Tel.: +33 1 45 58 71 00

or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Tuning light to kill deep cancer tumors: Nanoparticles developed at UMass Medical School advance potential clinical application for photodynamic therapy October 15th, 2014

Announcements

HP Supercomputer at NREL Garners Top Honor October 19th, 2014

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

Events/Classes

Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014

Aspen Aerogels, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 October 17th, 2014

New VDMA Association "Electronics, Micro and Nano Technologies" founded: Inaugural Meeting in Frankfurt/Main, Germany October 15th, 2014

Nanotronics Imaging Releases nSPEC® 3D, Powerful Microscope That Captures 3D Images at Nanoscale, in Lightning Speed: Company Unveils Design at American Chemical Society 2014 International Elastomer Conference October 14th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE